Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks ...

GILD's full-year Zacks Consensus Estimates ... these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a ...

On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $90.22 which represents a slight increase of $0.38 or 0.42% from the prior close of $89.84. The stock opened at ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Gilead is expected to post earnings of $1.62 ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Gilead is expected to ...

GILD) have crossed above the average analyst 12-month target price of $85.46, changing hands for $85.83/share. When a stock reaches the target an analyst has set, the analyst logically has two ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...